This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
Celldex (CLDX) Down 3.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Celldex (CLDX) Down 2.3% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD
by Zacks Equity Research
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Mallinckrodt Enrolls First Patient in Liver Disease Study
by Zacks Equity Research
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
Regeneron Ebola Treatment Shows Promise, Study Stopped Early
by Zacks Equity Research
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 28.21% and -43.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Celldex (CLDX) Down 29.2% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
by Zacks Equity Research
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.
Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Celldex Therapeutics (CLDX) closed at $5.92, marking a -1.17% move from the previous day.
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Why Is Celldex (CLDX) Down 29% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 46.67% and -54.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Celldex Therapeutics (CLDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.